A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers.

Drug Des Devel Ther · 2017 · PMC5411174 · PMID 28479852

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

29 , 30 In the present study, an increasing trend in body temperature after administration of DWP05195 was observed, and five cases of hyperthermia (maximum 38.3°C) were reported.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.